Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy

Blood

Volumn 129, Issue 11, 2017, Pages 1437-1447

  Chauvet, Sophie ^a,b,c   Frémeaux Bacchi, Véronique ^b,d   Petitprez, Florent ^b   Karras, Alexandre ^a   Daniel, Laurent ^e   Burtey, Stéphane ^e   Choukroun, Gabriel ^f   Delmas, Yahsou ^g   Guerrot, Dominique ^h   François, Arnaud ^h   Le Quintrec, Moglie ⁱ   Javaugue, Vincent ^j,k   Ribes, David ^l   Vrigneaud, Laurence ^m   Arnulf, Bertrand ⁿ   Goujon, Jean Michel ^j,k   Ronco, Pierre ^o   Touchard, Guy ^j,k   Bridoux, Frank ^j,k  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e HÔPITAL DE LA CONCEPTION   (France)

^f AMIENS UNIVERSITY HOSPITAL   (France)

^g BORDEAUX UNIVERSITY HOSPITAL   (France)

^h ROUEN UNIVERSITY HOSPITAL   (France)

ⁱ FOCH HOSPITAL   (France)

^j POITIERS UNIVERSITY HOSPITAL   (France)

^k UNIVERSITÉ DE POITIERS   (France)

^l TOULOUSE UNIVERSITY HOSPITAL   (France)

^m CENTRE HOSPITALIER DE VALENCIENNES   (France)

ⁿ SAINT LOUIS HOSPITAL   (France)

^o HÔPITAL TENON   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BORTEZOMIB; COMPLEMENT COMPONENT C3; COMPLEMENT MEMBRANE ATTACK COMPLEX; CORTICOSTEROID; CYCLOPHOSPHAMIDE; MELPHALAN; MYCOPHENOLATE MOFETIL; PREDNISONE; RITUXIMAB;

ADULT; AGED; B LYMPHOCYTE; CHRONIC KIDNEY FAILURE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CLINICAL OUTCOME; COHORT ANALYSIS; CONFERENCE PAPER; CONSERVATIVE TREATMENT; CORTICOSTEROID THERAPY; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENETIC SCREENING; GLOMERULOPATHY; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOCLONAL GAMMOPATHY ASSOCIATED C3 GLOMERULOPATHY; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEINURIA; RETROSPECTIVE STUDY; COMPLICATION; DRUG THERAPY; FACTUAL DATABASE; FRANCE; GLOMERULUS; KIDNEY DISEASES; MOLECULARLY TARGETED THERAPY; PARAPROTEINEMIAS; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; B-LYMPHOCYTES; COHORT STUDIES; COMPLEMENT C3; DATABASES, FACTUAL; DRUG THERAPY; FRANCE; HUMANS; KIDNEY DISEASES; KIDNEY GLOMERULUS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PARAPROTEINEMIAS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85012846473     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-08-737163     Document Type: Conference Paper

References (31)

1. Bridoux F, Leung N, Hutchison CA, et al; International Kidney and Monoclonal Gammopathy Research Group. Diagnosis of monoclonal gammopathy of renal significance. Kidney Int. 2015;87(4):698-711.
2. Fermand J-P, Bridoux F, Kyle RA, et al; International Kidney and Monoclonal Gammopathy Research Group. How I treat monoclonal gammopathy of renal significance (MGRS). Blood. 2013;122(22):3583-3590.
3. Fakhouri F, Frémeaux-Bacchi V, Noël L-H, Cook HT, Pickering MC. C3 glomerulopathy: a new classification. Nat Rev Nephrol. 2010;6(8): 494-499.
4. Servais A, Frémeaux-Bacchi V, Lequintrec M, et al. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet. 2007;44(3):193-199.
5. Pickering MC, D'Agati VD, Nester CM, et al. C3 glomerulopathy: consensus report. Kidney Int. 2013;84(6):1079-1089.
6. Hou J, Markowitz GS, Bomback AS, et al. Toward a working definition of C3 glomerulopathy by immunofluorescence. Kidney Int. 2014;85(2): 450-456.
7. Servais A, Noël L-H, Roumenina LT, et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 2012; 82(4):454-464.
8. Sethi S, Fervenza FC, Zhang Y, et al. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol. 2011;6(5):1009-1017.
9. Appel GB, Cook HT, Hageman G, et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol. 2005;16(5):1392-1403.
10. Smith RJH, Harris CL, Pickering MC. Dense deposit disease. Mol Immunol. 2011;48(14): 1604-1610.
11. Sethi S, Sukov WR, Zhang Y, et al. Dense deposit disease associated with monoclonal gammopathy of undetermined significance. Am J Kidney Dis. 2010;56(5):977-982.
12. Bridoux F, Desport E, Frémeaux-Bacchi V, et al. Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association? Clin J Am Soc Nephrol. 2011;6(9): 2165-2174.
13. Zand L, Kattah A, Fervenza FC, et al. C3 glomerulonephritis associated with monoclonal gammopathy: a case series. Am J Kidney Dis. 2013;62(3):506-514.
14. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130(6):461-470.
15. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1-S266.
16. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749-757.
17. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
18. Leung N, Bridoux F, Hutchison CA, et al; International Kidney and Monoclonal Gammopathy Research Group. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood. 2012;120(22):4292-4295.
19. Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines-application to the individual patient. Kidney Int. 2012;82(8):840-856.
20. Durie BGM, Harousseau J-L, Miguel JS, et al; International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-1473.
21. Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30(36):4541-4549.
22. Roumenina LT, Loirat C, Dragon-Durey M-A, Halbwachs-Mecarelli L, Sautes-Fridman C, Fremeaux-Bacchi V. Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods. 2011;365(1-2): 8-26.
23. Frémeaux-Bacchi V, Weiss L, Brun P, Kazatchkine MD. Selective disappearance of C3NeF IgG autoantibody in the plasma of a patient with membranoproliferative glomerulonephritis following renal transplantation. Nephrol Dial Transplant. 1994; 9(7):811-814.
24. Bomback AS, Smith RJ, Barile GR, et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol. 2012; 7(5):748-756.
25. Nester CM, Smith RJ. Treatment options for C3 glomerulopathy. Curr Opin Nephrol Hypertens. 2013;22(2):231-237.
26. Vivarelli M, Pasini A, Emma F. Eculizumab for the treatment of dense-deposit disease. N Engl J Med. 2012;366(12):1163-1165.
27. Giaime P, Daniel L, Burtey S. Remission of C3 glomerulopathy with rituximab as only immunosuppressive therapy. Clin Nephrol. 2015; 83(1):57-60.
28. Rabasco C, Cavero T, Román E, et al; Spanish Group for the Study of Glomerular Diseases (GLOSEN). Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int. 2015; 88(5):1153-1160.
29. Blanc C, Togarsimalemath SK, Chauvet S, et al. Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases. J Immunol. 2015;194(11): 5129-5138.
30. Jokiranta TS, Solomon A, Pangburn MK, Zipfel PF, Meri S. Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H. J Immunol. 1999;163(8): 4590-4596.
31. Zhang Y, Nester CM, Martin B, et al. Defining the complement biomarker profile of C3 glomerulopathy. Clin J Am Soc Nephrol. 2014;9(11):1876-1882.